Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib, melphalan, and prednisone in combination with daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible.
Maria-Victoria Mateos, MD, PhD, a physician and director of the myeloma program at the University of Salamanca, Spain, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib (Velcade), melphalan, and prednisone (VMP) in combination with daratumumab (Darzalex; DARA; D-VMP) in patients with newly diagnosed multiple myeloma who are transplant ineligible.
After a median follow-up of 28 months, D-VMP was superior to VMP in terms of overall response rate, complete response rate, and progression-free survival (PFS), Mateos says. PFS acted as a surrogate marker for overall survival.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More